International Cancer Genome Consortium
Korean Cohort
Powered by SNPnexus
Overview
Help
Sex
Survival Status
Age at Diagnosis
Loading...
Cancer Genome Interpreter (CGI) help
| Gene | Protein Alteration | Alteration Match | Drug | Effect | Tumour | Evidence |
|---|---|---|---|---|---|---|
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (intron_variant) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NOTCH2 | NOTCH2 MUT* (S851S) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | Sorafenib (Pan-TK inhibitor) | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | Pan-RAF inhibitor | Responsive | PRAD | Pre-clinical |
| RAF1 | RAF1 MUT* (intron_variant) | Different Alteration | U0126 (MEK inhibitor) | Responsive | PRAD | Pre-clinical |
| TP53 | TP53 MUT (Q165*) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Q165*) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Q165*) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Q165*) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Q165*) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Q165*) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Q165*) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q165*) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q165*) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Q165*) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Q165*) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Q165*) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q165*) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Q165*) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Q165*) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | BRAF inhibitor | Resistant | CM | Case report |
| AKT1 | AKT1 MUT (E17K) | Complete Match | allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | non-allosteric AKT inhibitor | Responsive | CANCER | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| AKT1 | AKT1 MUT (E17K) | Complete Match | Temsirolimus (MTOR inhibitor) | Responsive | ED | Early trials |
| AKT1 | AKT1 MUT (E17K) | Complete Match | AKT inhibitor | Responsive | CANCER | Pre-clinical |
| AKT1 | AKT1 MUT (E17K) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | FH | Case report |
| NTRK3 | NTRK3 MUT* (R459W) | Different Alteration | IGF1R inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R459W) | Different Alteration | PI3K pathway inhibitor | Responsive | BRCA | Pre-clinical |
| NTRK3 | NTRK3 MUT* (R459W) | Different Alteration | Midostaurin (Pan-TK inhibitor) | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (G244C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G244C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G244C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G244C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G244C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G244C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G244C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G244C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G244C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G244C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G244C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G244C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G244C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G244C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G244C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (H1047L) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (H1047L) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| MET | MET MUT* (A48A) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NOTCH2 | NOTCH2 MUT* (A3S), NOTCH2 MUT* (A3V) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (H193R) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (H193R) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (H193R) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (H193R) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | NOTCH2 MUT* (5-UTRSNV) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (G199V) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (G199V) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (G199V) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (G199V) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NOTCH2 | NOTCH2 MUT* (5-UTRSNV), NOTCH2 MUT* (intron_variant) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| GATA3 | GATA3 MUT (splice_donor_variant) | Complete Match | Aromatase ihibitor | Responsive | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (C420R) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (C420R) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Different Mutation | BRAF inhibitor | Resistant | CM | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BLCA, HNC | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | HNSC | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | G, THCA | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | Everolimus;Trastuzumab;Chemotherapy (MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy) | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | COREAD | Pre-clinical |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | ED, OV, CESC | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive | BRCA | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PIK3CA inhibitor | Responsive | ST | Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | AKT inhibitor | Responsive | BRCA | Early trials |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | PI3K pathway inhibitor | Responsive;Responsive | L | Pre-clinical;Case report |
| PIK3CA | PIK3CA MUT (E542K) | Complete Match | Cetuximab (EGFR mAb inhibitor) | Resistant | COREAD | Late trials |
| PIK3CA | PIK3CA MUT (E542K) | Different Alteration | PI3K pathway inhibitor | Resistant | BRCA | Pre-clinical |
| ABL1 | ABL1 MUT* (A922V), ABL1 MUT* (E921D) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (A922V), ABL1 MUT* (E921D) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (A922V), ABL1 MUT* (E921D) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (A922V), ABL1 MUT* (E921D) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (A922V), ABL1 MUT* (E921D) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (A922V), ABL1 MUT* (E921D) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| TP53 | TP53 MUT (R175H) | Complete Match | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (R175H) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (R175H) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (R175H) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (R175H) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| NRG1 | NRG1 MUT* (intron_variant) | Different Alteration | Lapatinib (ERBB2 inhibitor) | Responsive | LUAD | Pre-clinical |
| NRG1 | NRG1 MUT* (intron_variant) | Different Alteration | Afatinib (ERBB2 & EGFR inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (A8A) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (A8A) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (A8A) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (A8A) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (A8A) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (A8A) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (A8A) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (A8A) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (A8A) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| PDGFB | PDGFB MUT* (L11V) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | DFS | FDA guidelines |
| TP53 | TP53 MUT (Y220C) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (Y220C) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (Y220C) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (Y220C) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C135W) | Different Mutation | HSP90 inhibitor | Responsive | CANCER | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | Decitabine (Chemotherapy) | Responsive | AML, MDPS | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | Abemaciclib (CDK4/6 inhibitor) | Resistant | BRCA | Early trials |
| TP53 | TP53 MUT (C135W) | Different Mutation | HDM2 inhibitor | Responsive | AML | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | Cisplatin (Chemotherapy) | Resistant | FGCT, MGCT | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | Gemcitabine (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | Mitomycin C (Chemotherapy) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | WEE1 inhibitor | Responsive | HNC | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | MDM2 inhibitor | Resistant | LIP | Early trials |
| TP53 | TP53 MUT (C135W) | Complete Match | Doxorubicin (Anthracycline antitumor antibiotic) | Responsive | BLCA | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Complete Match | WEE1 inhibitor | Responsive | OV | Early trials |
| TP53 | TP53 MUT (C135W) | Different Alteration | Pramlintide (Amylin analogue) | Responsive | THYM | Pre-clinical |
| TP53 | TP53 MUT (C135W) | Different Alteration | AZD6738 (ATR inhibitor) | Responsive | BCL | Early trials |
| SETD2 | SETD2 MUT (R424*) | Complete Match | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SETD2 | SETD2 MUT (R424*) | Different Alteration | WEE1 inhibitor | Responsive | CANCER | Pre-clinical |
| SF3B1 | SF3B1 MUT (K700E) | Complete Match | Spliceosome inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q152*) | Complete Match | EZH2 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q152*) | Complete Match | PD1 inhibitor | Responsive | OV | Pre-clinical |
| ARID1A | ARID1A MUT (Q152*) | Complete Match | PARP inhibitor | Responsive | CANCER | Pre-clinical |
| ARID1A | ARID1A MUT (Q152*) | Complete Match | ATR inhibitor | Responsive | CANCER | Pre-clinical |
| EGFR | EGFR MUT* (T629T) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (T629T) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| ABL1 | ABL1 MUT* (T729T) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| ABL1 | ABL1 MUT* (T729T) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (T729T) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| ABL1 | ABL1 MUT* (T729T) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| ABL1 | ABL1 MUT* (T729T) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| ABL1 | ABL1 MUT* (T729T) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| PML | PML MUT* (intron_variant) | Different Alteration | Volasertib (PLK1 inhibitor) | Responsive | AML | Early trials |
| PML | PML MUT* (intron_variant) | Different Alteration | Tretinoin (Retinoid) | Responsive | APML | FDA guidelines |
| PML | PML MUT* (intron_variant) | Different Alteration | Tretinoin;Arsenic Trioxide (Retinoid;Chemotherapy) | Responsive | AML | FDA guidelines |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | Nintedanib (Pan-TK inhibitor) | Responsive | LUAD | Case report |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | RET inhibitor | Responsive | LUAD | Pre-clinical |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | LUAD | Early trials |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | Vandetanib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | Sunitinib (Pan-TK inhibitor) | Responsive | THCA | Pre-clinical |
| RET | RET MUT* (D489N), RET MUT* (S904S), RET MUT* (A510A), RET MUT* (G691S), RET MUT* (L769L), RET MUT* (intron_variant), RET MUT* (A45A), RET MUT* (R67H) | Different Alteration | RET inhibitor | Responsive | TH | Pre-clinical |
| KMT2A | MLL MUT* (N3797N) | Different Alteration | EPZ-5676 (DOT1L inhibitor) | Responsive | ALL, MDS, AML | Early trials |
| KMT2A | MLL MUT* (N3797N) | Different Alteration | BET inhibitor | Responsive | ALL | Pre-clinical |
| KMT2A | MLL MUT* (N3797N) | Different Alteration | BET inhibitor | Responsive | AML | Pre-clinical |
| KMT2A | MLL MUT* (N3797N) | Different Alteration | Daunorubicin (Chemotherapy) | Responsive | AML | FDA guidelines |
| KMT2A | MLL MUT* (N3797N) | Different Alteration | Belinostat (HDAC inhibitor) | Responsive | AML | Early trials |
| KMT2A | MLL MUT* (N3797N) | Different Alteration | DOT1L inhibitor | Responsive | AML | Early trials |
| NTRK1 | NTRK1 MUT* (A629A) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Case report |
| NTRK1 | NTRK1 MUT* (A629A) | Different Alteration | Pan-TKR inhibitor | Responsive | CANCER | Early trials |
| NTRK1 | NTRK1 MUT* (A629A) | Different Alteration | Pan-TK inhibitor | Responsive | LUAD | Pre-clinical |
| NTRK1 | NTRK1 MUT* (A629A) | Different Alteration | Pan-TK inhibitor | Responsive | COREAD | Case report |
| EGFR | EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (intron_variant) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| JAK2 | JAK2 MUT* (H163H) | Different Alteration | Ruxolitinib (JAK inhibitor) | Responsive | ALL | Pre-clinical |
| ROS1 | ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | IM | Case report |
| ROS1 | ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ROS1 | ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) | Different Alteration | Cabozantinib (Pan-kinase inhibitor) | Responsive | LUAD | Case report |
| ROS1 | ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Pre-clinical |
| ROS1 | ROS1 MUT* (T145P), ROS1 MUT* (D1776H), ROS1 MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD | Early trials |
| MET | MET MUT* (P1382P), MET MUT* (D1304D), MET MUT* (intron_variant), MET MUT* (A1357A) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | G | Case report |
| NOTCH1 | NOTCH1 MUT* (P284P) | Different Alteration | Gamma secretase inhibitor | Responsive | ALL | Pre-clinical |
| NOTCH1 | NOTCH1 MUT* (P284P) | Different Alteration | Gamma secretase inhibitor | Responsive | BRCA | Pre-clinical |
| ERBB4 | ERBB4 MUT* (intron_variant) | Different Alteration | Lapatinib;Afatinib (ERBB2 inhibitor;ERBB2 & EGFR inhibitor) | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;SRC inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | GB, LY | Early trials |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Lorlatinib (ALK&ROS1 inhibitor) | Responsive | NSCLC | Early trials |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | THCA, IM | Case report |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | HSP90 inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | IM, COREAD | Case report |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Crizotinib (ALK inhibitor) | Responsive | LUAD, NSCLC | FDA guidelines |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Brigatinib (Pan-TK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Entrictinib (Pan-TK inhibitor) | Responsive | COREAD | Case report |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | LUAD | FDA guidelines |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | HSP90 inhibitor (HSP90 inhibitor) | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;IGF1R inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor;MEK inhibitor | Responsive | LUAD | Pre-clinical |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | novel ALK inhibitor | Responsive | LUAD | Early trials |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Ceritinib (ALK inhibitor) | Responsive | HEMATO | Early trials |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | ALK inhibitor | Responsive | COREAD | Case report |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | Alectinib (ALK inhibitor) | Responsive | NSCLC | FDA guidelines |
| ALK | ALK MUT* (G845G), ALK MUT* (intron_variant) | Different Alteration | MEK inhibitor (ALK inhibitor;MEK inhibitor) | Responsive | LUAD | Pre-clinical |
| PDGFRA | PDGFRA MUT* (intron_variant) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| FGFR3 | FGFR3 MUT* (intron_variant), FGFR3 MUT* (N294N) | Different Alteration | FGFR inhibitor | Responsive | BLCA | Case report |
| FGFR3 | FGFR3 MUT* (intron_variant), FGFR3 MUT* (N294N) | Different Alteration | FGFR inhibitor | Responsive | G | Early trials |
| FGFR3 | FGFR3 MUT* (intron_variant), FGFR3 MUT* (N294N) | Different Alteration | FGFR inhibitor | Responsive | NSCLC | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (intron_variant) | Different Alteration | DNA-PKc inhibitor | Responsive | PRAD | Pre-clinical |
| TMPRSS2 | TMPRSS2 MUT* (intron_variant) | Different Alteration | PARP inhibitor | Responsive | PRAD | Pre-clinical |
| BCR | BCR MUT* (P312P) | Different Alteration | Ponatinib (BCR-ABL inhibitor & Pan-TK inhibitor) | Responsive | CML, ALL | FDA guidelines |
| BCR | BCR MUT* (P312P) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | ALL, CML | FDA guidelines |
| BCR | BCR MUT* (P312P) | Different Alteration | Nilotinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (P312P) | Different Alteration | Bosutinib (BCR-ABL inhibitor) | Responsive | CML | FDA guidelines |
| BCR | BCR MUT* (P312P) | Different Alteration | Dasatinib;Venetoclax (BCR-ABL inhibitor;BCL2 inhibitor) | Responsive | ALL | Pre-clinical |
| BCR | BCR MUT* (P312P) | Different Alteration | Dasatinib (BCR-ABL inhibitor) | Responsive | ALL, CML | FDA guidelines |
| EGFR | EGFR MUT* (D994D) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | L | Case report |
| EGFR | EGFR MUT* (D994D) | Different Alteration | Erlotinib (EGFR inhibitor) | Responsive | NSCLC | Case report |
| PDGFRA | PDGFRA MUT* (V84V) | Different Alteration | Imatinib (BCR-ABL inhibitor & KIT inhibitor) | Responsive | MDPS, MDS, ECL, HES | FDA guidelines |
| STK11 | STK11 MUT (splice_donor_variant) | Different Mutation | Everolimus (MTOR inhibitor) | Responsive | PA | Case report |
| STK11 | STK11 MUT (splice_donor_variant) | Complete Match | Phenformin (Anti-diabetic) | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (splice_donor_variant) | Complete Match | MTOR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | STK11 MUT (splice_donor_variant) | Complete Match | BET inhibitor | Resistant | L | Pre-clinical |
| STK11 | STK11 MUT (splice_donor_variant) | Complete Match | PD1 inhibitor | Resistant | CANCER | Early trials |
| STK11 | STK11 MUT (splice_donor_variant) | Complete Match | SRC inhibitor;PI3K/MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (splice_donor_variant) | Complete Match | MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (splice_donor_variant) | Different Alteration | MTOR inhibitor | Responsive | CANCER | Pre-clinical |
| STK11 | STK11 MUT (splice_donor_variant) | Different Alteration | PD1 inhibitor | Resistant | CANCER | Early trials |
| STK11 | STK11 MUT (splice_donor_variant) | Different Alteration | Phenformin (Anti-diabetic) | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (splice_donor_variant) | Different Alteration | MEK inhibitor | Responsive | LUAD | Pre-clinical |
| STK11 | STK11 MUT (splice_donor_variant) | Different Alteration | SRC inhibitor;PI3K/MEK inhibitor | Responsive | LUAD | Pre-clinical |
| Variation | Gene | Transcript | Protein Alteration | Consequence | Tumour Driver | Oncogenic Classification |
|---|
Loading...
Drug-Gene Interactions help
Druggable categories in the cohort
No meaningful categories found
Focus the search to a gene of interest:
Loading...
| Gene | Interaction Source | Interaction Types | Drug Claim Primary Name | Drug Name | ChEMBL ID |
|---|---|---|---|---|---|
| PIK3CA | MyCancerGenome | inhibitor | INK-1117 | INK-1117 | CHEMBL3545055 |
| PIK3CA | CKB | MS417 | |||
| PIK3CA | CIViC | RAPAMYCIN (SIROLIMUS) | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CGI | Chemotherapy | |||
| PIK3CA | CKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | HS-173 | ||
| PIK3CA | CKB | Linsitinib | LINSITINIB | CHEMBL1091644 | |
| PIK3CA | CKB | ZSTK474 | ZSTK-474 | CHEMBL586701 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AMG319 | AMG-319 | CHEMBL3545048 |
| PIK3CA | MyCancerGenome | inhibitor | BKM120 | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | ClearityFoundationBiomarkers | BYL719 | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | NCI | I3C | INDOLE-3-CARBINOL | CHEMBL155625 | |
| PIK3CA | CKB | GDC-0941 | PICTILISIB | CHEMBL521851 | |
| PIK3CA | CKB | Navitoclax | NAVITOCLAX | CHEMBL443684 | |
| PIK3CA | CIViC | PICTILISIB | PICTILISIB | CHEMBL521851 | |
| PIK3CA | ChemblInteractions | inhibitor | SF-1126 | SF-1126 | CHEMBL2326966 |
| PIK3CA | ClearityFoundationBiomarkers | DS-7423 | DS-7423 | CHEMBL3545248 | |
| PIK3CA | GuideToPharmacologyInteractions | allosteric modulator | PIK-108 | ||
| PIK3CA | CKB | Neratinib | NERATINIB | CHEMBL180022 | |
| PIK3CA | CGI | Cetuximab | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD8186 | AZD-8186 | CHEMBL3545424 |
| PIK3CA | CKB | DS-7423 | DS-7423 | CHEMBL3545248 | |
| PIK3CA | OncoKB | Copanlisib | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | NCI | SERM | |||
| PIK3CA | CKB | ASN003 | |||
| PIK3CA | CIViC | PP242 | |||
| PIK3CA | CKB | AZD6482 | AZD-6482 | CHEMBL2165191 | |
| PIK3CA | CIViC | BYL719 (ALPELISIB) | |||
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | CKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | CKB | GDC-0980 | APITOLISIB | CHEMBL1922094 | |
| PIK3CA | CKB | Radiotherapy | |||
| PIK3CA | CKB | Palbociclib | PALBOCICLIB | CHEMBL189963 | |
| PIK3CA | CKB | LY2780301 | LY-2780301 | CHEMBL3545134 | |
| PIK3CA | NCI | RAS INHIBITOR | |||
| PIK3CA | OncoKB | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | NCI | HGF | |||
| PIK3CA | CIViC | EVEROLIMUS | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | CKB | Tamoxifen | TAMOXIFEN | CHEMBL83 | |
| PIK3CA | CKB | Trametinib | TRAMETINIB | CHEMBL2103875 | |
| PIK3CA | NCI | RAPAMYCIN | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CKB | TGX-221 | |||
| PIK3CA | MyCancerGenome | inhibitor | GDC-0032 | TASELISIB | CHEMBL2387080 |
| PIK3CA | ChemblInteractions | inhibitor | PILARALISIB | PILARALISIB (CHEMBL3360203) | CHEMBL3360203 |
| PIK3CA | ChemblInteractions | inhibitor | PWT-33587 | PWT-33587 | CHEMBL3545006 |
| PIK3CA | ChemblInteractions | inhibitor | RECILISIB | RECILISIB | CHEMBL2219421 |
| PIK3CA | CIViC | CETUXIMAB | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | CIViC | LAPATINIB | LAPATINIB | CHEMBL554 | |
| PIK3CA | CKB | CUDC-907 | CUDC-907 | CHEMBL3545052 | |
| PIK3CA | CKB | VS-5584 | VS-5584 | CHEMBL1079593 | |
| PIK3CA | CKB | Lapatinib | LAPATINIB | CHEMBL554 | |
| PIK3CA | CKB | Selumetinib | SELUMETINIB | CHEMBL1614701 | |
| PIK3CA | CKB | GSK2126458 | OMIPALISIB | CHEMBL1236962 | |
| PIK3CA | NCI | SELECTIVE ESTROGEN RECEPTOR MODULATOR | |||
| PIK3CA | OncoKB | Letrozole | LETROZOLE | CHEMBL1444 | |
| PIK3CA | CKB | GSK1059615 | GSK-1059615 | CHEMBL3544966 | |
| PIK3CA | ChemblInteractions | inhibitor | PA-799 | PA-799 | CHEMBL1684984 |
| PIK3CA | CKB | ARQ092 | ARQ-092 | CHEMBL3545422 | |
| PIK3CA | CKB | BGJ398 | INFIGRATINIB | CHEMBL1852688 | |
| PIK3CA | ChemblInteractions | inhibitor | TASELISIB | TASELISIB | CHEMBL2387080 |
| PIK3CA | MyCancerGenome | inhibitor | XL147 | PILARALISIB (CHEMBL3218575) | CHEMBL3218575 |
| PIK3CA | ChemblInteractions | inhibitor | VS-5584 | VS-5584 | CHEMBL1079593 |
| PIK3CA | OncoKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| PIK3CA | TdgClinicalTrial | RIGOSERTIB | RIGOSERTIB | CHEMBL1241855 | |
| PIK3CA | CKB | Cisplatin | |||
| PIK3CA | ChemblInteractions | inhibitor | COPANLISIB | COPANLISIB | CHEMBL3218576 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI 3-KG INHIBITOR II | CHEMBL1231533 | CHEMBL1231533 |
| PIK3CA | CIViC | PERIFOSINE | PERIFOSINE | CHEMBL372764 | |
| PIK3CA | ChemblInteractions | inhibitor | PF-04691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | ChemblInteractions | inhibitor | SONOLISIB | SONOLISIB | CHEMBL411907 |
| PIK3CA | ChemblInteractions | inhibitor | PKI-179 | PKI-179 | CHEMBL1258517 |
| PIK3CA | MyCancerGenome | inhibitor | GDC-0980 | APITOLISIB | CHEMBL1922094 |
| PIK3CA | CKB | Demcizumab | DEMCIZUMAB | CHEMBL2109384 | |
| PIK3CA | NCI | FLAVOPIRIDOL | ALVOCIDIB | CHEMBL428690 | |
| PIK3CA | NCI | PKC412 | MIDOSTAURIN | CHEMBL608533 | |
| PIK3CA | ChemblInteractions | inhibitor | CUDC-907 | CUDC-907 | CHEMBL3545052 |
| PIK3CA | CKB | P7170 | Panulisib | CHEMBL3545322 | |
| PIK3CA | ClearityFoundationBiomarkers | GSK2126458 | OMIPALISIB | CHEMBL1236962 | |
| PIK3CA | CKB | MLN0128 | INK-128 | CHEMBL3545056 | |
| PIK3CA | CancerCommons | inhibitor | BKM120 | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | OncoKB | Serabelisib | YOHIMBINE | CHEMBL15245 | |
| PIK3CA | ChemblInteractions | inhibitor | INK-1117 | INK-1117 | CHEMBL3545055 |
| PIK3CA | NCI | IL-2 | |||
| PIK3CA | CKB | Bevacizumab | BEVACIZUMAB | CHEMBL1201583 | |
| PIK3CA | MyCancerGenome | inhibitor | GSK2636771 | GSK-2636771 | CHEMBL3188551 |
| PIK3CA | CKB | PKI-179 | PKI-179 | CHEMBL1258517 | |
| PIK3CA | ClearityFoundationBiomarkers | BAY80-6946 | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | CIViC | PALBOCICLIB (PD0332991) | PALBOCICLIB | CHEMBL189963 | |
| PIK3CA | CKB | Idelalisib | IDELALISIB | CHEMBL2216870 | |
| PIK3CA | ChemblInteractions | inhibitor | LY-3023414 | LY-3023414 | CHEMBL3544999 |
| PIK3CA | CIViC | TEMSIROLIMUS | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CIViC | AZD5363 | AZD-5363 | CHEMBL2178577 | |
| PIK3CA | NCI | THEAFLAVINS | |||
| PIK3CA | CIViC | IDELALISIB | IDELALISIB | CHEMBL2216870 | |
| PIK3CA | NCI | PTHRP | |||
| PIK3CA | CKB | GSK2334470 | CHEMBL1765740 | CHEMBL1765740 | |
| PIK3CA | CKB | Doxil | |||
| PIK3CA | CIViC | CISPLATIN | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LY 294002 | LY-294002 | CHEMBL98350 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ECF309 | ||
| PIK3CA | ClearityFoundationBiomarkers | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | ClearityFoundationBiomarkers | ZSTK474 | ZSTK-474 | CHEMBL586701 | |
| PIK3CA | NCI | RALOXIFENE | RALOXIFENE | CHEMBL81 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PIK-75 | ||
| PIK3CA | ChemblInteractions | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | Ponatinib | PONATINIB | CHEMBL1171837 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | CH5132799 | PA-799 | CHEMBL1684984 |
| PIK3CA | CIViC | ANTI-EGFR MONOCLONAL ANTIBODY | |||
| PIK3CA | ClearityFoundationBiomarkers | TEMSIROLIMUS | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CKB | BAY1125976 | BAY-1125976 | CHEMBL3545049 | |
| PIK3CA | CKB | Sirolimus | SIROLIMUS | CHEMBL413 | |
| PIK3CA | CKB | GSK2141795 | UPROSERTIB | CHEMBL3137336 | |
| PIK3CA | MyCancerGenome | inhibitor | PI-103 | PI-103 | CHEMBL573339 |
| PIK3CA | CKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | APITOLISIB | APITOLISIB | CHEMBL1922094 |
| PIK3CA | ChemblInteractions | inhibitor | RG-7666 | RG-7666 | CHEMBL3545324 |
| PIK3CA | CKB | Doxorubicin | DOXORUBICIN | CHEMBL53463 | |
| PIK3CA | CKB | LY294002 | LY-294002 | CHEMBL98350 | |
| PIK3CA | CKB | AT-7867 | CHEMBL428462 | CHEMBL428462 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | BGT-226 | ||
| PIK3CA | NCI | SULINDAC | SULINDAC | CHEMBL15770 | |
| PIK3CA | NCI | CAMPTOTHECIN | CAMPTOTHECIN | CHEMBL65 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | TASELISIB | TASELISIB | CHEMBL2387080 |
| PIK3CA | CKB | WEHI-539 | |||
| PIK3CA | CKB | GDC-0032 | TASELISIB | CHEMBL2387080 | |
| PIK3CA | CKB | Fluorouracil | FLUOROURACIL | CHEMBL185 | |
| PIK3CA | MyCancerGenome | inhibitor | PKI-587 | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | ChemblInteractions | inhibitor | ZSTK-474 | ZSTK-474 | CHEMBL586701 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | BUPARLISIB | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | CancerCommons | inhibitor | BEZ235 | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | YM-024 | |||
| PIK3CA | CKB | PKI-402 | CHEMBL589258 | CHEMBL589258 | |
| PIK3CA | CIViC | PI3K INHIBITOR | |||
| PIK3CA | ChemblInteractions | inhibitor | BGT-226 | BGT-226 (CHEMBL3545096) | CHEMBL3545096 |
| PIK3CA | CKB | Vistusertib | BENZONATATE | CHEMBL1374379 | |
| PIK3CA | CKB | Paclitaxel | PACLITAXEL | CHEMBL428647 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LENIOLISIB | ||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PQR309 | ||
| PIK3CA | TdgClinicalTrial | SF1126 | SF-1126 | CHEMBL2326966 | |
| PIK3CA | CKB | FOLFOX | |||
| PIK3CA | CKB | rigosertib | RIGOSERTIB | CHEMBL1241855 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PICTILISIB | PICTILISIB | CHEMBL521851 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | NCI | STZ | STREPTOZOTOCIN | CHEMBL1651906 | |
| PIK3CA | NCI | HERBIMYCIN A | HERBIMYCIN | CHEMBL479533 | |
| PIK3CA | CKB | Sapanisertib | INK-128 | CHEMBL3545056 | |
| PIK3CA | CKB | A-443654 | A-443654 | CHEMBL379300 | |
| PIK3CA | CKB | AZD8055 | AZD-8055 | CHEMBL1801204 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD8835 | CANDICIDIN | CHEMBL1200647 |
| PIK3CA | MyCancerGenome | inhibitor | XL-765 | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | OMIPALISIB | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | OncoKB | Taselisib | TASELISIB | CHEMBL2387080 | |
| PIK3CA | OncoKB | Ribociclib | Ribociclib | CHEMBL3545110 | |
| PIK3CA | ChemblInteractions | inhibitor | GSK-1059615 | GSK-1059615 | CHEMBL3544966 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | AZD6482 | AZD-6482 | CHEMBL2165191 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | PKI-587 | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 28 [PMID: 24387221] | ||
| PIK3CA | CKB | Pertuzumab | PERTUZUMAB | CHEMBL2007641 | |
| PIK3CA | MyCancerGenome | inhibitor | SF1126 | SF-1126 | CHEMBL2326966 |
| PIK3CA | CKB | Fulvestrant | FULVESTRANT | CHEMBL1358 | |
| PIK3CA | CKB | OSI-027 | OSI-027 | CHEMBL3120215 | |
| PIK3CA | ChemblInteractions | inhibitor | APITOLISIB | APITOLISIB | CHEMBL1922094 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI-103 | PI-103 | CHEMBL573339 |
| PIK3CA | ChemblInteractions | inhibitor | VOXTALISIB | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ZSTK474 | ZSTK-474 | CHEMBL586701 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | TG-100-115 | TG100-115 | CHEMBL230011 |
| PIK3CA | CKB | PI-103 | PI-103 | CHEMBL573339 | |
| PIK3CA | MyCancerGenome | inhibitor | PWT33597 | ||
| PIK3CA | NCI | PACLITAXEL | PACLITAXEL | CHEMBL428647 | |
| PIK3CA | CKB | U0126 | U-0126 | CHEMBL100473 | |
| PIK3CA | CIViC | RADIATION | |||
| PIK3CA | CKB | Lucitanib | LUCITANIB | CHEMBL2220486 | |
| PIK3CA | OncoKB | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | CKB | Torin 1 | TORIN1 | CHEMBL1256459 | |
| PIK3CA | CKB | Carboxyamidotriazole Orotate | |||
| PIK3CA | CKB | ARQ 751 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | GEDATOLISIB | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | CKB | AZD8835 | CANDICIDIN | CHEMBL1200647 | |
| PIK3CA | CKB | 5-FU | FLUOROURACIL | CHEMBL185 | |
| PIK3CA | ClearityFoundationBiomarkers | XL-147 | |||
| PIK3CA | NCI | RESVERATROL | RESVERATROL | CHEMBL165 | |
| PIK3CA | CKB | Letrozole | LETROZOLE | CHEMBL1444 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | GSK2126458 | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | CKB | SAR245409 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | ABT-263 | NAVITOCLAX | CHEMBL443684 | |
| PIK3CA | CKB | Cetuximab | CETUXIMAB | CHEMBL1201577 | |
| PIK3CA | MyCancerGenome | inhibitor | BGJ398 | ||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PILARALISIB | PILARALISIB (CHEMBL3360203) | CHEMBL3360203 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | VS-5584 | VS-5584 | CHEMBL1079593 |
| PIK3CA | CancerCommons | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | CKB | NVP-AEW541 | AEW-541 | CHEMBL551064 | |
| PIK3CA | CIViC | CH5132799 | PA-799 | CHEMBL1684984 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | CUDC-907 | CUDC-907 | CHEMBL3545052 |
| PIK3CA | CKB | BKM120 | BUPARLISIB | CHEMBL2017974 | |
| PIK3CA | OncoKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | CIViC | BEZ235 (NVP-BEZ235, DACTOLISIB) | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | ChemblInteractions | inhibitor | DS-7423 | DS-7423 | CHEMBL3545248 |
| PIK3CA | CKB | CH5132799 | PA-799 | CHEMBL1684984 | |
| PIK3CA | CKB | Regorafenib | REGORAFENIB | CHEMBL1946170 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | SERABELISIB | YOHIMBINE | CHEMBL15245 |
| PIK3CA | CGI | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PP121 | CHEMBL1081312 | CHEMBL1081312 |
| PIK3CA | CKB | Temsirolimus | TEMSIROLIMUS | CHEMBL1201182 | |
| PIK3CA | CKB | A-1210477 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | IDELALISIB | IDELALISIB | CHEMBL2216870 |
| PIK3CA | CKB | MLN1117 | INK-1117 | CHEMBL3545055 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | KU-0060648 | CHEMBL1086377 | CHEMBL1086377 |
| PIK3CA | NCI | DHEA | PRASTERONE | CHEMBL90593 | |
| PIK3CA | CKB | Dabrafenib | DABRAFENIB | CHEMBL2028663 | |
| PIK3CA | NCI | UROKINASE-TYPE PLASMINOGEN ACTIVATOR | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 11J [PMID: 23021994] | ||
| PIK3CA | ChemblInteractions | inhibitor | OMIPALISIB | OMIPALISIB | CHEMBL1236962 |
| PIK3CA | CKB | Ridaforolimus | RIDAFOROLIMUS | CHEMBL2103839 | |
| PIK3CA | MyCancerGenome | inhibitor | PF-4691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | CKB | Copanlisib | COPANLISIB | CHEMBL3218576 | |
| PIK3CA | NCI | BCG | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PF-04691502 | PF-04691502 | CHEMBL1234354 |
| PIK3CA | OncoKB | LJM716 | |||
| PIK3CA | OncoKB | Olaparib | OLAPARIB | CHEMBL521686 | |
| PIK3CA | NCI | 17-AAG | CHEMBL126955 | CHEMBL126955 | |
| PIK3CA | NCI | NSAID | |||
| PIK3CA | MyCancerGenome | inhibitor | GDC-0941 | PICTILISIB | CHEMBL521851 |
| PIK3CA | ChemblInteractions | inhibitor | AZD-6482 | AZD-6482 | CHEMBL2165191 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | WORTMANNIN | WORTMANNIN | CHEMBL428496 |
| PIK3CA | CKB | GS-9820 | Acalisib | CHEMBL3545397 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | NEMIRALISIB | ||
| PIK3CA | CKB | Torkinib | |||
| PIK3CA | CKB | PD-0325901 | PD-0325901 | CHEMBL507361 | |
| PIK3CA | CKB | Gemcitabine | GEMCITABINE | CHEMBL888 | |
| PIK3CA | CKB | Deguelin | DEGUELIN | CHEMBL393417 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | INK-128 | INK-128 | CHEMBL3545056 |
| PIK3CA | CKB | Dasatinib | DASATINIB | CHEMBL1421 | |
| PIK3CA | CancerCommons | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | NCI | TRAIL | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | PI 3-KG INHIBITOR | CHEMBL568150 | CHEMBL568150 |
| PIK3CA | NCI | GM-CSF | REGRAMOSTIM | CHEMBL2107881 | |
| PIK3CA | MyCancerGenome | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | CKB | CCT128930 | CHEMBL263664 | CHEMBL263664 | |
| PIK3CA | TdgClinicalTrial | PWT33597 | |||
| PIK3CA | NCI | ZINC SULFATE | ZINC SULFATE | CHEMBL1200929 | |
| PIK3CA | CKB | trastuzumab emtansine | TRASTUZUMAB EMTANSINE | CHEMBL1743082 | |
| PIK3CA | CKB | A66 | PHENMETRAZINE | CHEMBL1201208 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | OncoKB | Fulvestrant | FULVESTRANT | CHEMBL1358 | |
| PIK3CA | MyCancerGenome | inhibitor | PX-866 | SONOLISIB | CHEMBL411907 |
| PIK3CA | MyCancerGenome | inhibitor | SOPHORETIN | QUERCETIN | CHEMBL50 |
| PIK3CA | CKB | BAY1082439 | BAY-1082439 | CHEMBL3545245 | |
| PIK3CA | CIViC | TRASTUZUMAB | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | NCI | CARBOPLATIN | CARBOPLATIN | CHEMBL1351 | |
| PIK3CA | NCI | ANTIANGIOGENIC | |||
| PIK3CA | MyCancerGenome | inhibitor | BEZ235 | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | CKB | PF-05212384 | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | CKB | WYE-125132 | |||
| PIK3CA | OncoKB | GDC-0077 | PHENMETRAZINE | CHEMBL1201208 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | ALPELISIB | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CIViC | CABOZANTINIB | CABOZANTINIB | CHEMBL2105717 | |
| PIK3CA | NCI | VINCRISTINE | VINCRISTINE | CHEMBL90555 | |
| PIK3CA | NCI | DOXORUBICIN | DOXORUBICIN | CHEMBL53463 | |
| PIK3CA | CKB | BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | ChemblInteractions | inhibitor | BAY-1082439 | BAY-1082439 | CHEMBL3545245 |
| PIK3CA | CKB | Afuresertib | AFURESERTIB | CHEMBL2219422 | |
| PIK3CA | CancerCommons | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | Floxuridine | FLOXURIDINE | CHEMBL917 | |
| PIK3CA | CancerCommons | inhibitor | XL765 | VOXTALISIB | CHEMBL3545366 |
| PIK3CA | ClearityFoundationBiomarkers | EVEROLIMUS | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | NCI | RETINOID | ETRETINATE | CHEMBL464 | |
| PIK3CA | CKB | DHM25 | |||
| PIK3CA | CKB | Gedatolisib | GEDATOLISIB | CHEMBL592445 | |
| PIK3CA | CKB | PWT33597 | |||
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | LY3023414 | LY-3023414 | CHEMBL3544999 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | COMPOUND 82 [PMID: 21332118] | ||
| PIK3CA | CKB | Camptothecin | CAMPTOTHECIN | CHEMBL65 | |
| PIK3CA | ChemblInteractions | inhibitor | WX-037 | WX-037 | CHEMBL3545385 |
| PIK3CA | CKB | Venetoclax | VENETOCLAX | CHEMBL3137309 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | QUINOSTATIN | ||
| PIK3CA | NCI | TYROSINE KINASE INHIBITORS | |||
| PIK3CA | ChemblInteractions | inhibitor | Puquitinib | Puquitinib | CHEMBL3545088 |
| PIK3CA | ChemblInteractions | inhibitor | PWT-33579 | PWT-33579 | CHEMBL3545323 |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BUPARLISIB HYDROCHLORIDE | BUPARLISIB HYDROCHLORIDE | CHEMBL2364604 |
| PIK3CA | CKB | ABT-737 | CHEMBL376408 | CHEMBL376408 | |
| PIK3CA | CIViC | PANITUMUMAB | PANITUMUMAB | CHEMBL1201827 | |
| PIK3CA | ChemblInteractions | inhibitor | GEDATOLISIB | GEDATOLISIB | CHEMBL592445 |
| PIK3CA | CKB | XL147 | PILARALISIB (CHEMBL3218575) | CHEMBL3218575 | |
| PIK3CA | CIViC | MK-2206 | MK-2206 | CHEMBL1079175 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | IPI549 | OXAZEPAM | CHEMBL568 |
| PIK3CA | CKB | BYL719 | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | ChemblInteractions | inhibitor | BUPARLISIB | BUPARLISIB | CHEMBL2017974 |
| PIK3CA | CKB | MK2206 | MK-2206 | CHEMBL1079175 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | DACTOLISIB | DACTOLISIB | CHEMBL1879463 |
| PIK3CA | ChemblInteractions | inhibitor | Panulisib | Panulisib | CHEMBL3545322 |
| PIK3CA | CKB | PD98509 | |||
| PIK3CA | CancerCommons | inhibitor | SAR260301 | SAR-260301 | CHEMBL3545008 |
| PIK3CA | CKB | Metformin | METFORMIN | CHEMBL1431 | |
| PIK3CA | CKB | Vemurafenib | VEMURAFENIB | CHEMBL1229517 | |
| PIK3CA | MyCancerGenomeClinicalTrial | inhibitor | BAY80-6946 | COPANLISIB | CHEMBL3218576 |
| PIK3CA | NCI | SURAMIN | SURAMIN | CHEMBL265502 | |
| PIK3CA | CKB | Capecitabine | CAPECITABINE | CHEMBL1773 | |
| PIK3CA | ClearityFoundationBiomarkers | XL765 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | Everolimus | EVEROLIMUS | CHEMBL1908360 | |
| PIK3CA | ClearityFoundationBiomarkers | NVP-BEZ235 | DACTOLISIB | CHEMBL1879463 | |
| PIK3CA | CKB | Pimasertib | PIMASERTIB | CHEMBL2107832 | |
| PIK3CA | MyCancerGenome | inhibitor | BYL719 | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | PF-04691502 | PF-04691502 | CHEMBL1234354 | |
| PIK3CA | CIViC | TASELISIB (GDC-0032) | |||
| PIK3CA | NCI | MILTEFOSINE | MILTEFOSINE | CHEMBL125 | |
| PIK3CA | NCI | QUERCETIN | QUERCETIN | CHEMBL50 | |
| PIK3CA | CGI | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | TdgClinicalTrial | XL765 | VOXTALISIB | CHEMBL3545366 | |
| PIK3CA | CKB | AT13148 | AT-13148 | CHEMBL3544960 | |
| PIK3CA | ChemblInteractions | inhibitor | ALPELISIB | ALPELISIB | CHEMBL2396661 |
| PIK3CA | CKB | Irinotecan | IRINOTECAN | CHEMBL481 | |
| PIK3CA | CKB | CGM097 | |||
| PIK3CA | CKB | MSC2363318A | MSC-2363318A | CHEMBL3545003 | |
| PIK3CA | CKB | PW12 | |||
| PIK3CA | NCI | 17-ALLYL-AMINOGELDANAMYCIN | CHEMBL126955 | CHEMBL126955 | |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | GDC-0077 | PHENMETRAZINE | CHEMBL1201208 |
| PIK3CA | CKB | CC-223 | CC-223 | CHEMBL3545151 | |
| PIK3CA | CKB | cobimetinib | COBIMETINIB | CHEMBL2146883 | |
| PIK3CA | NCI | CPT-11 | IRINOTECAN | CHEMBL481 | |
| PIK3CA | OncoKB | Buparlisib | BUPARLISIB | CHEMBL2017974 | |
| PIK3CA | NCI | IL-11 | |||
| PIK3CA | CKB | Trastuzumab | TRASTUZUMAB | CHEMBL1201585 | |
| PIK3CA | OncoKB | ASN003 | |||
| PIK3CA | CKB | Sorafenib | SORAFENIB | CHEMBL1336 | |
| PIK3CA | CKB | PF-4989216 | |||
| PIK3CA | CKB | TAK-733 | TAK-733 | CHEMBL1615025 | |
| PIK3CA | CKB | LY3023414 | LY-3023414 | CHEMBL3544999 | |
| PIK3CA | CKB | PX-866 | SONOLISIB | CHEMBL411907 | |
| PIK3CA | CKB | Bortezomib | BORTEZOMIB | CHEMBL325041 | |
| PIK3CA | CKB | Carboplatin | CARBOPLATIN | CHEMBL1351 | |
| PIK3CA | ChemblInteractions | inhibitor | PICTILISIB | PICTILISIB | CHEMBL521851 |
| PIK3CA | OncoKB | Alpelisib | ALPELISIB | CHEMBL2396661 | |
| PIK3CA | CKB | Ipatasertib | IPATASERTIB | CHEMBL2177390 | |
| PIK3CA | ClearityFoundationBiomarkers | PF-04691502 | PF-04691502 | CHEMBL1234354 | |
| PIK3CA | CKB | Topotecan | TOPOTECAN | CHEMBL84 | |
| PIK3CA | CIViC | RIBOCICLIB | Ribociclib | CHEMBL3545110 | |
| PIK3CA | ChemblInteractions | inhibitor | MLN-1117 | MLN-1117 | CHEMBL3545379 |
| PIK3CA | GuideToPharmacologyInteractions | inhibitor | DUVELISIB | DUVELISIB | CHEMBL3039502 |
Phenotype
Protein
DrugThere are patients available from the BCN Biobank that match the selected/a subset of the criteria. Explore the data available for these patients using our Cohort Browser.
Researchers can request samples from BCNB website to support their research activities.
*Based on your filtering criteria you can view the number of available patients and associated samples in BCNBIn order to apply for samples, please use the BCNB Request System to submit an Expression of interest (EOI) form.
If you require further details please contact us at tissue.bank@breastcancernow.org
| Patient ID | Age at Diagnosis | Sex | Survival Status | Survival Time | Follow up | Recurrence Type | Stage |
|---|---|---|---|---|---|---|---|
| DO228246 | 26 | female | deceased | 1.23 | relapse | distant recurrence_metastasis | 3 |
| DO228247 | 33 | female | deceased | 9.74 | relapse | distant recurrence_metastasis | 3 |
| DO228256 | 29 | female | alive | 8.72 | complete remission | NA | 2 |
| DO228260 | 32 | female | alive | 11.41 | complete remission | NA | 2 |
| DO228262 | 33 | female | alive | 14.66 | complete remission | NA | 2 |
| DO228266 | 33 | female | deceased | 14.27 | relapse | distant recurrence_metastasis | 2 |
| DO228268 | 35 | female | alive | 19.17 | complete remission | NA | 2 |
| DO228272 | 32 | female | alive | 15.56 | complete remission | NA | 2 |
| DO228276 | 32 | female | alive | 17.39 | relapse | local recurrence and distant metastasis | 2 |
| DO228283 | 33 | female | alive | 19.53 | relapse | local recurrence and distant metastasis | 3 |
| DO228290 | 31 | female | alive | 16.09 | complete remission | NA | 2 |
| DO228293 | 28 | female | alive | 16.36 | complete remission | NA | 2 |
| DO228295 | 31 | female | deceased | 9.86 | relapse | distant recurrence_metastasis | 2 |
| DO228300 | 35 | female | alive | 3.59 | complete remission | NA | 2 |
| DO228307 | 35 | female | alive | 18.58 | relapse | distant recurrence_metastasis | 2 |
| DO228310 | 33 | female | deceased | 0.58 | complete remission | NA | 2 |
| DO228319 | 35 | female | alive | 17.78 | complete remission | NA | 1 |
| DO228321 | 35 | female | deceased | 16.16 | relapse | distant recurrence_metastasis | 2 |
| DO228332 | 33 | female | alive | 18.01 | complete remission | NA | 2 |
| DO228340 | 34 | female | deceased | 3.96 | complete remission | NA | 3 |
| DO228350 | 34 | female | alive | 11.57 | complete remission | NA | 1 |
| DO228356 | 33 | female | deceased | 14.07 | relapse | distant recurrence_metastasis | 2 |
| DO228383 | 30 | female | alive | 14.99 | complete remission | NA | 2 |
| DO228404 | 29 | female | alive | 14.09 | complete remission | NA | 1 |
| DO228409 | 31 | female | alive | 16.67 | complete remission | NA | 1 |
| DO228423 | 34 | female | alive | 15.59 | complete remission | NA | 2 |
| DO228426 | 35 | female | alive | 15.57 | complete remission | NA | 2 |
| DO228427 | 31 | female | alive | 15.06 | complete remission | NA | 2 |
| DO228430 | 31 | female | alive | 17.52 | complete remission | NA | 1 |
| DO228431 | 32 | female | alive | 10.99 | complete remission | NA | 2 |
| DO228433 | 34 | female | alive | 7.27 | complete remission | NA | 3 |
| DO228439 | 33 | female | alive | 6.96 | complete remission | NA | 1 |
| DO228441 | 29 | female | deceased | 0.55 | complete remission | NA | 1 |
| DO228449 | 27 | female | alive | 18.46 | complete remission | NA | 2 |
| DO228452 | 32 | female | deceased | 5.1 | relapse | distant recurrence_metastasis | 2 |
| DO228453 | 34 | female | alive | 15.67 | complete remission | NA | 0 |
| DO228455 | 34 | female | alive | 11.74 | complete remission | NA | 1 |
| DO228460 | 25 | female | alive | 12.76 | complete remission | NA | 2 |
| DO228471 | 28 | female | alive | 6.89 | complete remission | NA | 2 |
| DO228477 | 33 | female | alive | 8.25 | complete remission | NA | 3 |
| DO228479 | 27 | female | alive | 7.48 | complete remission | NA | 2 |
| DO228483 | 34 | female | alive | 7.52 | complete remission | NA | 0 |
| DO228488 | 30 | female | alive | 3.74 | complete remission | NA | 2 |
| DO228499 | 29 | female | alive | 1.07 | complete remission | NA | 1 |
| DO228502 | 27 | female | alive | 0.62 | complete remission | NA | 1 |
| DO228506 | 32 | female | alive | 1.84 | complete remission | NA | 1 |
| DO228509 | 33 | female | alive | 1.42 | complete remission | NA | 1 |
| DO228516 | 35 | female | alive | 1.69 | complete remission | NA | 2 |
| DO228521 | 32 | female | alive | 1.08 | complete remission | NA | 1 |
| DO229483 | 34 | female | alive | 1.13 | complete remission | NA | 0 |